August 14, 2025

Valencia Technologies Secures $35 Million Investment for eCoin® System

News Summary

Valencia Technologies, based in California, has received a strategic $35 million investment to promote its innovative eCoin system for treating urgency urinary incontinence (UUI). This funding from Brooks Advisory Group aims to accelerate commercialization. The newly appointed CEO, James D. Surek, brings extensive experience in medical devices. The eCoin system, recently approved by the FDA, is the first subcutaneous implantable tibial nerve stimulator for UUI, promising significant improvements in patients’ quality of life with minimal invasiveness.

California – Valencia Technologies, a medical device company based in Valencia, California, has secured a strategic investment of up to $35 million to enhance the commercialization of its innovative eCoin® system, which is designed for treating urgency urinary incontinence (UUI). This funding comes from Brooks Advisory Group, a subsidiary of Brooks Management Group (BMG), and is aimed at accelerating the company’s growth and market penetration.

Alongside this investment, Valencia Technologies has appointed James D. Surek as its new Chief Executive Officer (CEO). Surek brings a wealth of experience in the medical device sector, having previously driven significant revenue growth and successful turnarounds in various organizations.

The eCoin® system is a groundbreaking treatment option that has recently received FDA approval, marking it as the first and only FDA-approved subcutaneous implantable tibial nerve stimulator for UUI. This condition affects millions of individuals, causing sudden urges to urinate that can lead to involuntary leakage. The eCoin device is a coin-sized neurostimulator implanted just under the skin near the ankle in a minimally invasive outpatient procedure. It provides periodic stimulation to the tibial nerve, which has been shown to reduce episodes of UUI by at least 50% in 75% of patients over a one-year period.

Investment and Commercial Strategy

With the new investment, Valencia Technologies plans to expedite market introduction of the eCoin system. Brooks Advisory Group will not only provide capital but will also assist in commercialization strategies, sales operations, reimbursement processes, payor services, and overall financial strategies, ensuring a robust framework for market entry.

Leadership Changes

James D. Surek’s appointment as CEO is a significant move for Valencia Technologies. His past accomplishments include leading Advanced Bionics to a revenue growth increase exceeding $200 million over a three-year period, culminating in a \$3 billion acquisition by Boston Scientific. Furthermore, Surek successfully turned around Entellus Medical, growing its revenue from less than $1 million to over $70 million and achieving an initial public offering (IPO) within four years.

Surek will join a management team that includes Dain Black, Ryan Brooks, and Jim Surek, in addition to current Board members Jeff Greiner and Don Hubbard. This experienced team is poised to leverage their collective expertise to drive the company’s growth.

Healthcare Implications

Dr. Jason Kim of Stony Brook Medicine has praised the eCoin system as an effective alternative for patients suffering from overactive bladder, likening its efficiency to that of established medications and more invasive options. The eCoin device is designed to streamline the post-implant experience, minimizing the need for regular follow-up programming sessions and eliminating the necessity for weekly recharging, which adds to its appeal for patients seeking effective treatment with less hassle.

The successful introduction of the eCoin device is expected to provide a vital solution for those affected by UUI, significantly enhancing the quality of life for many individuals. The funding secured by Valencia Technologies will enable the company to reach a wider audience and meet the growing demand for minimally invasive solutions in healthcare.

As Valencia Technologies moves forward with its plans for development and commercialization under the leadership of James D. Surek, the company stands positioned to become a key player in the rapidly evolving field of neuromodulation and medical devices targeting urinary incontinence.